These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 35900750)

  • 1. Epstein-Barr virus-associated posttransplant lymphoproliferative disorders: new insights in pathogenesis, classification and treatment.
    Dierickx D; Pociupany M; Natkunam Y
    Curr Opin Oncol; 2022 Sep; 34(5):413-421. PubMed ID: 35900750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Late-onset posttransplant Epstein-Barr virusrelated lymphoproliferative disease after cord blood transplantation for chronic active Epstein Barr virus infection: A case report.
    Yamamoto M; Shindo M; Funayama T; Sumi C; Saito T; Toki Y; Hatayama M; Imadome KI; Mizukami Y; Okumura T
    Medicine (Baltimore); 2022 Mar; 101(12):e29055. PubMed ID: 35357349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T-cell posttransplant lymphoproliferative disorders after allogeneic hematopoietic cell transplantation.
    Kuno M; Ito A; Maeshima AM; Taniguchi H; Tanaka T; Inamoto Y; Kurosawa S; Kim SW; Fukuda T
    Int J Hematol; 2020 Aug; 112(2):193-199. PubMed ID: 32472530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective Epstein-Barr virus-related post-transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first-line treatment.
    Chiereghin A; Prete A; Belotti T; Gibertoni D; Piccirilli G; Gabrielli L; Pession A; Lazzarotto T
    Transpl Infect Dis; 2016 Feb; 18(1):44-54. PubMed ID: 26574232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Latest update on immunotherapy of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease].
    Hao QF; Sheng GY; Luan Z
    Zhongguo Dang Dai Er Ke Za Zhi; 2013 Sep; 15(9):795-9. PubMed ID: 24034931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epstein-Barr virus related post-transplant lymphoproliferative disorder prevention strategies in allogeneic hematopoietic stem cell transplantation.
    Lindsay J; Yong MK; Greenwood M; Kong DCM; Chen SCA; Rawlinson W; Slavin M
    Rev Med Virol; 2020 Jul; 30(4):e2108. PubMed ID: 32301566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epstein-Barr virus-associated post-transplantation lymphoproliferative disorder: potential treatments and implications for nursing practice.
    Jiménez S
    Clin J Oncol Nurs; 2015 Feb; 19(1):94-8. PubMed ID: 25689655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases.
    Styczynski J; Einsele H; Gil L; Ljungman P
    Transpl Infect Dis; 2009 Oct; 11(5):383-92. PubMed ID: 19558376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting.
    Paya CV; Fung JJ; Nalesnik MA; Kieff E; Green M; Gores G; Habermann TM; Wiesner PH; Swinnen JL; Woodle ES; Bromberg JS
    Transplantation; 1999 Nov; 68(10):1517-25. PubMed ID: 10589949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epstein Barr virus-directed T-cell therapy for refractory EBV-PTLD in a toddler post Orthotopic heart transplantation.
    Work E; Gupta D; Slayton WB; Rees J; Coppola JA; Seifert R; Bleiweis MS; Jacobs JP; Peek G; Philip J; Brock A; Rivera JH; Sullivan K; Narasimhulu SS
    Pediatr Transplant; 2024 Mar; 28(2):e14707. PubMed ID: 38419558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epstein-Barr virus post-transplant lymphoproliferative disease (PTLD) after hematopoietic stem cell transplantation.
    Ru Y; Chen J; Wu D
    Eur J Haematol; 2018 Sep; 101(3):283-290. PubMed ID: 29949208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How I treat posttransplant lymphoproliferative disorder.
    Amengual JE; Pro B
    Blood; 2023 Oct; 142(17):1426-1437. PubMed ID: 37540819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarkers for PTLD diagnosis and therapies.
    Martinez OM
    Pediatr Nephrol; 2020 Jul; 35(7):1173-1181. PubMed ID: 31240394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Post-Transplant Lymphoproliferative Disorders.
    Aghsaeifard Z; Alizadeh R
    Cardiovasc Hematol Disord Drug Targets; 2022; 22(2):96-103. PubMed ID: 35927798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
    Styczynski J; Gil L; Tridello G; Ljungman P; Donnelly JP; van der Velden W; Omar H; Martino R; Halkes C; Faraci M; Theunissen K; Kalwak K; Hubacek P; Sica S; Nozzoli C; Fagioli F; Matthes S; Diaz MA; Migliavacca M; Balduzzi A; Tomaszewska A; Camara Rde L; van Biezen A; Hoek J; Iacobelli S; Einsele H; Cesaro S;
    Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-transplant lymphoproliferative disorders.
    Singavi AK; Harrington AM; Fenske TS
    Cancer Treat Res; 2015; 165():305-27. PubMed ID: 25655616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies.
    Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
    Ann Hematol; 2019 Sep; 98(9):2163-2177. PubMed ID: 31243569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival outcomes of allogeneic hematopoietic cell transplants with EBV-positive or EBV-negative post-transplant lymphoproliferative disorder, A CIBMTR study.
    Naik S; Riches M; Hari P; Kim S; Chen M; Bachier C; Shaughnessy P; Hill J; Ljungman P; Battiwalla M; Chhabra S; Daly A; Storek J; Ustun C; Diaz MA; Cerny J; Beitinjaneh A; Yared J; Brown V; Page K; Dahi PB; Ganguly S; Seo S; Chao N; Freytes CO; Saad A; Savani BN; Woo Ahn K; Boeckh M; Heslop HE; Lazarus HM; Auletta JJ; Kamble RT
    Transpl Infect Dis; 2019 Oct; 21(5):e13145. PubMed ID: 31301099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of use of Epstein-Barr viral load in patients after allogeneic stem cell transplantation to diagnose and monitor posttransplant lymphoproliferative disease.
    Gärtner BC; Schäfer H; Marggraff K; Eisele G; Schäfer M; Dilloo D; Roemer K; Laws HJ; Sester M; Sester U; Einsele H; Mueller-Lantzsch N
    J Clin Microbiol; 2002 Feb; 40(2):351-8. PubMed ID: 11825941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epstein-Barr virus-related post-transplant lymphoproliferative disease (EBV-PTLD) in the setting of allogeneic stem cell transplantation: a comprehensive review from pathogenesis to forthcoming treatment modalities.
    Al Hamed R; Bazarbachi AH; Mohty M
    Bone Marrow Transplant; 2020 Jan; 55(1):25-39. PubMed ID: 31089285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.